Display options
Cite
Zenkov RG, Vlasova OA, Maksimova VP, et al. Molecular Mechanisms of Anticancer Activity of N-Glycosides of Indolocarbazoles LCS-1208 and LCS-1269. Molecules. 2021;26(23)doi: 10.3390/molecules26237329.
Zenkov, R. G., Vlasova, O. A., Maksimova, V. P., Fetisov, T. I., Karpechenko, N. Y., Ektova, L. V., Eremina, V. A., Popova, V. G., Usalka, O. G., Lesovaya, E. A., Belitsky, G. A., Yakubovskaya, M. G., & Kirsanov, K. I. (2021). Molecular Mechanisms of Anticancer Activity of N-Glycosides of Indolocarbazoles LCS-1208 and LCS-1269. Molecules (Basel, Switzerland), 26(23), . https://doi.org/10.3390/molecules26237329
Zenkov, Roman G, et al. "Molecular Mechanisms of Anticancer Activity of N-Glycosides of Indolocarbazoles LCS-1208 and LCS-1269." Molecules (Basel, Switzerland) vol. 26,23 (2021). doi: https://doi.org/10.3390/molecules26237329
Zenkov RG, Vlasova OA, Maksimova VP, Fetisov TI, Karpechenko NY, Ektova LV, Eremina VA, Popova VG, Usalka OG, Lesovaya EA, Belitsky GA, Yakubovskaya MG, Kirsanov KI. Molecular Mechanisms of Anticancer Activity of N-Glycosides of Indolocarbazoles LCS-1208 and LCS-1269. Molecules. 2021 Dec 02;26(23). doi: 10.3390/molecules26237329. PMID: 34885910; PMCID: PMC8658795.
Copy Download .nbib Format: NLM
Share it on

Molecules. 2021 Dec 02;26(23). doi: 10.3390/molecules26237329.

Molecular Mechanisms of Anticancer Activity of N-Glycosides of Indolocarbazoles LCS-1208 and LCS-1269.

Molecules (Basel, Switzerland)

Roman G Zenkov, Olga A Vlasova, Varvara P Maksimova, Timur I Fetisov, Natalia Y Karpechenko, Lidiya V Ektova, Vera A Eremina, Valeriia G Popova, Olga G Usalka, Ekaterina A Lesovaya, Gennady A Belitsky, Marianna G Yakubovskaya, Kirill I Kirsanov

Affiliations

  1. N. N. Blokhin Russian Cancer Research Center, 24 Kashirskoe Shosse, 115478 Moscow, Russia.
  2. Faculty of Biotechnology and Industrial Ecology, Mendeleev University of Chemical Technology of Russia, 9 Miusskaya Ploshchad, 125047 Moscow, Russia.
  3. International School "Medicine of the Future", I.M. Sechenov First Moscow State Medical University, 8-2 Trubetskaya St., 119991 Moscow, Russia.
  4. Department of Oncology, I.P. Pavlov Ryazan State Medical University, 9 Vysokovoltnaya St., 390026 Ryazan, Russia.
  5. Institute of Medicine, RUDN University, 6 Miklukho-Maklaya St., 117198 Moscow, Russia.

PMID: 34885910 PMCID: PMC8658795 DOI: 10.3390/molecules26237329

Abstract

Novel indolocarbazole derivatives named LCS were synthesized by our research group. Two of them were selected as the most active anticancer agents in vivo. We studied the mechanisms of anticancer activity in accordance with the previously described effects of indolocarbazoles. Cytotoxicity was estimated by MTT assay. We analyzed LCS-DNA interactions by circular dichroism in cholesteric liquid crystals and fluorescent indicator displacement assay. The effect on the activity of topoisomerases I and II was studied by DNA relaxation assay. Expression of interferon signaling target genes was estimated by RT-PCR. Chromatin remodeling was analyzed-the effect on histone H1 localization and reactivation of epigenetically silenced genes. LCS-induced change in the expression of a wide gene set was counted by means of PCR array. Our study revealed the cytotoxic activity of the compounds against 11 cancer cell lines and it was higher than in immortalized cells. Both compounds bind DNA; binding constants were estimated-LCS-1208 demonstrated higher affinity than LCS-1269; it was shown that LCS-1208 intercalates into DNA that is typical for rebeccamycin derivatives. LCS-1208 also inhibits topoisomerases I and IIα. Being a strong intercalator and topoisomerase inhibitor, LCS-1208 upregulates the expression of interferon-induced genes. In view of LCSs binding to DNA we analyzed their influence on chromatin stability and revealed that LCS-1269 displaces histone H1. Our analysis of chromatin remodeling also included a wide set of epigenetic experiments in which LCS-1269 demonstrated complex epigenetic activity. Finally, we revealed that the antitumor effect of the compounds is based not only on binding to DNA and chromatin remodeling but also on alternative mechanisms. Both compounds induce expression changes in genes involved in neoplastic transformation and target genes of the signaling pathways in cancer cells. Despite of being structurally similar, each compound has unique biological activities. The effects of LCS-1208 are associated with intercalation. The mechanisms of LCS-1269 include influence on higher levels such as chromatin remodeling and epigenetic effects.

Keywords: LCS-1208; LCS-1269; antitumor activity; chromatin remodeling; epigenetics; indolocarbazoles; intercalation; interferon

References

  1. Chem Rev. 2012 Jun 13;112(6):3193-328 - PubMed
  2. J Antibiot (Tokyo). 1992 Feb;45(2):189-94 - PubMed
  3. Expert Rev Hematol. 2009 Feb;2(1):17-26 - PubMed
  4. Nucleic Acids Res. 2017 Jan 9;45(1):198-205 - PubMed
  5. Immunity. 2015 Feb 17;42(2):332-343 - PubMed
  6. Proc Natl Acad Sci U S A. 2010 May 25;107(21):9620-5 - PubMed
  7. Mol Pharmacol. 1999 Feb;55(2):377-85 - PubMed
  8. Oncogene. 2002 Mar 7;21(11):1727-38 - PubMed
  9. J Med Chem. 1999 May 20;42(10):1816-22 - PubMed
  10. J Biol Chem. 2010 Jan 1;285(1):422-33 - PubMed
  11. Adv Protein Chem Struct Biol. 2013;92:1-62 - PubMed
  12. Nat Prod Rep. 2006 Dec;23(6):1007-45 - PubMed
  13. Biochemistry. 2001 Feb 27;40(8):2564-71 - PubMed
  14. Cold Spring Harb Perspect Med. 2016 Oct 3;6(10): - PubMed
  15. Chem Rev. 2018 Sep 26;118(18):9058-9128 - PubMed
  16. J Biol Chem. 2001 Jul 6;276(27):25302-8 - PubMed
  17. Curr Genomics. 2017 Feb;18(1):75-92 - PubMed
  18. Curr Med Chem Anticancer Agents. 2002 Mar;2(2):255-66 - PubMed
  19. J Med Chem. 1996 Oct 25;39(22):4471-7 - PubMed
  20. Biochemistry. 1997 Apr 1;36(13):3917-29 - PubMed
  21. Drugs Today (Barc). 2017 Oct;53(10):531-543 - PubMed
  22. Saudi Med J. 2017 Mar;38(3):237-244 - PubMed
  23. Curr Top Med Chem. 2003;3(3):305-20 - PubMed
  24. Eur J Biochem. 1995 Nov 15;234(1):317-22 - PubMed
  25. J Antibiot (Tokyo). 1995 Jul;48(7):535-48 - PubMed
  26. Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):14973-8 - PubMed
  27. Immunity. 2013 May 23;38(5):870-80 - PubMed
  28. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4842-5 - PubMed
  29. Oncologist. 2002;7 Suppl 3:12-9 - PubMed
  30. J Antibiot (Tokyo). 1991 Jul;44(7):723-8 - PubMed
  31. Nat Commun. 2013;4:1908 - PubMed
  32. J Med Chem. 2005 Apr 7;48(7):2336-45 - PubMed
  33. Mol Cancer Ther. 2016 May;15(5):806-18 - PubMed
  34. Biochem J. 2003 Oct 15;375(Pt 2):255-62 - PubMed
  35. J Mol Biol. 1989 Dec 5;210(3):587-99 - PubMed
  36. Nat Struct Biol. 1997 Oct;4(10):796-801 - PubMed
  37. Curr Colorectal Cancer Rep. 2017 Apr;13(2):101-110 - PubMed
  38. Mutat Res. 2007 Oct 1;623(1-2):3-13 - PubMed
  39. Cancer Res. 2016 Jun 15;76(12):3446-50 - PubMed
  40. Mol Cancer Ther. 2007 Jun;6(6):1877-85 - PubMed
  41. Int J Biol Macromol. 2005 Jul;36(1-2):103-15 - PubMed
  42. J Phys Chem B. 2016 Sep 1;120(34):8942-52 - PubMed
  43. Cancer Res. 2003 Sep 1;63(17):5559-63 - PubMed
  44. mBio. 2017 Apr 4;8(2): - PubMed
  45. Trends Pharmacol Sci. 1989 Jun;10(6):218-20 - PubMed
  46. Eur J Med Chem. 2003 Feb;38(2):123-40 - PubMed
  47. Bioorg Med Chem. 2003 Nov 17;11(23):4871-9 - PubMed
  48. PLoS One. 2021 Jun 11;16(6):e0252504 - PubMed
  49. Elife. 2018 Feb 05;7: - PubMed
  50. Nat Protoc. 2007;2(6):1445-57 - PubMed
  51. Beilstein J Org Chem. 2013 Oct 10;9:2048-78 - PubMed

Publication Types

Grant support